Cell and Gene Therapy Contract Development and Manufacturing Organization Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rise in CGT Clinical Pipeline

Over 2,000 active programs are in development, a figure that dwarfs the capacity commissioned before 2024.^{[1]Science Translational Medicine, “Emerging Cell and Gene Therapies,” sciencemag.org} The US FDA created the Office of Therapeutic Products to streamline reviews and anticipates double-digit approvals each year through 2025. Each candidate demands bespoke viral-vector or cell-expansion workflows, expertise that most sponsors lack internally, increasing reliance on specialized cell therapy CDMO partners. Commercial approvals such as Casgevy, Lyfgenia, and prademagene zamikeracel validate demand and trigger multi-batch clinical supply orders. North America and Europe host 80% of trials, straining local facilities and allowing premium pricing. The driver, therefore, underpins sustained double-digit growth for the cell and gene therapy contract development and manufacturing organization market.

Rising Prevalence of Genetic Diseases & Cancer

Roughly 400 million patients live with a genetic disorder, and global cancer incidence is increasing 2–3% a year.^{[2].Journal of Cellular and Molecular Medicine, “Genetic Disease Burden,” onlinelibrary.wiley.com}Precision-medicine advances have unlocked previously untreatable targets using vector-based approaches. CAR-T therapies now command list prices of USD 400,000–500,000 and demonstrate the willingness of payers to reimburse one-time interventions.^{[3]FDA, “Office of Therapeutic Products Guidance,” fda.gov} Ageing demographics in high-income regions swell the eligible population, while contingency approvals for diabetes and cardiovascular gene therapies hint at mainstream uptake. CDMOs well-positioned to supply larger batch sizes will benefit most as the indication size widens.

VC & Big-Pharma Funding Surge

Biopharma companies and venture funds poured more than USD 15 billion into CGT deals during 2024. Novo Holdings’ USD 16.5 billion Catalent buyout underscores strategic intent to secure capacity. Capital flows shorten the time from discovery to Phase I, translating to a rising orderbook for process development and GMP lots. The influx is regionally skewed: 74% of disclosed financings originated in the United States and Europe, which exacerbates capacity imbalances relative to APAC. The trend fuels both supply additions and demand creation, accelerating revenue for the cell and gene therapy contract development and manufacturing organization market.

Outsourcing Preference of Small CGT Developers

Building a dedicated vector or cell-processing suite costs USD 50–100 million and can take 18–24 months. Start-ups, therefore, outsource activities such as process optimization, fill-finish, and analytical testing—even larger firms hedge risk by reserving external slots to avoid plant downtime. Robotic systems like Cellular Origins’ NeedleE™ and Cytiva’s Chronicle™ improve reproducibility yet remain capital-intensive, further steering innovators toward CDMOs with installed automation. The pattern is strongest in the United States, where demand for skilled labour outstrips supply, lifting order lead times to 9–12 months.

Limited High-Throughput Analytics for Large-Scale AAV Production

Complete AAV lot release now demands up to four weeks, largely due to capsid-ratio assays and genome integrity tests. Slow analytical turnaround restricts campaign throughput and inflates inventory costs. Equipment vendors are launching automation modules, but regulatory validation prolongs adoption. The bottleneck is pronounced in US and European plants, where compliance expectations remain highest. CDMOs investing in inline analytics and machine-learning-driven release will achieve competitive differentiation.

Complex, Manual-Intensive Manufacturing & Regulatory Hurdles

Viral-vector purification and cell-handling steps still rely on operator interventions, contributing 40–60% to COGS. Manual activity raises batch-failure risk and complicates scale-up. Concurrently, the 2024 FDA guidance expanded documentation on comparability and potency assays. Combined complexity elongates tech-transfer timelines and raises barriers for new entrants. Incremental automation—robotic line loading, closed-system harvest, and AI-driven scheduling—promises relief but demands validation programmes that newly capitalised CDMOs must fund.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segment Analysis

Cell therapy commanded 69.98% of the cell and gene therapy contract development and manufacturing organization market in 2025, buoyed by six commercial CAR-T products and an expanding allogeneic pipeline. Stem-cell platforms account for the largest share in cell therapy, favoured for established expansion, cryopreservation, and QC workflows. Engineered cell approaches such as CAR-NK and γδ T cells are gaining speed as improved gene-editing tools shorten development cycles. Despite its smaller base, gene therapy is projected to register a 16.85% CAGR through 2031, closing the gap swiftly. Viral vectors—particularly AAV—retain pricing power given their safety and tissue-tropism advantages. The first FDA-cleared European-manufactured batch of Iovance’s AMTAGVI in 2024 underscored commercial viability and opened cross-border supply lines. Non-viral modalities, notably lipid nanoparticles and minicircle DNA, are drawing capital because they can circumvent immunogenicity and scaling issues inherent to viral systems.

Batch sizes for allogeneic cell therapies are forecast to rise fivefold, driving demand for 2,000 L closed bioreactors and automated sterile welding systems. Gene therapy manufacturing, once restricted to 200 L batches, is rapidly migrating to 1,000 L–2,000 L single-use fermenters, compressing the cost per dose. Synergies exist: CDMOs with dual-capability suites can cross-utilize upstream operations, raising asset utilization rates and cushioning the impact of any one modality cycle.

Pre-clinical and R&D projects represented 70.25% of the cell and gene therapy contract development and manufacturing organization market in 2025 because the majority of pipeline assets remain in discovery or IND-enabling phases. Sponsors purchase small lots, often under 5 L, for formulation screening, vector mapping, and proof-of-concept studies. While volumes are modest, margins sit above 40% due to limited competition and high value-added consulting baked into contracts. As the pipeline matures, the number of Phase II and Phase III projects requiring GMP clinical supply is expanding at 14% annually, moving demand into more systematized, lower-margin production.

Although commercial manufacturing accounts for only 9.35% of 2025 volumes, it is the fastest-growing segment, with a 14.92% CAGR to 2031. Commercial production commands premium long-term contracts, often five-year take-or-pay structures, which help CDMOs amortize capital builds. However, the quality of life from commercial revenues is tempered by heightened regulatory scrutiny and warranty clauses that expose providers to batch liability. CDMOs are investing in redundant clean modular rooms and SAP-integrated MES platforms to pass FDA pre-approval inspections without delays.

Contract manufacturing held 35.20% of the cell and gene therapy development and manufacturing organization market in 2025, encompassing both clinical and commercial batch production. Underpinning demand is the scarcity of BSL-2/BSL-2+ compliant suites, which many innovators regard as a structural hurdle. GMP manufacturing revenues are now advancing at a 13.05% CAGR to 2031, thanks to the swell of Phase III studies requiring validated, reproducible lots; CDMOs with global quality systems benefit most. Process-development engagements remain sticky, averaging 18–24 months, and create a funnel for future GMP contracts.

Analytical services, once an ancillary revenue stream, are becoming mission-critical. The cell and gene therapy contract development and manufacturing organization market share for analytical testing is expected to rise as CDMOs expand vector genome titer assays, potency testing, and release analytics in-house for speed. Fill-finish, cryogenic packaging, and last-mile logistics capture client demand for integrated offerings. A shift toward pay-as-you-go testing and cloud-based data hand-off platforms improves transparency yet requires investment in cybersecurity and LIMS harmonization.

Geography Analysis

North America Cell and Gene Therapy Contract Development and Manufacturing Organization Market

North America generated 43.75% of global revenue in 2025, supported by the FDA’s clear pathways, a dense cluster of start-ups, and an investor base willing to underwrite early clinical studies. The United States alone hosted more than 60% of active trials, compelling CDMOs such as Thermo Fisher to commit USD 475 million for a Princeton expansion and Samsung Biologics to allocate capacity through strategic partnerships. However, the region’s cost base and a tightening labour pool inflate delivery times. CDMOs respond by raising process-development fees and offering workforce-training partnerships with community colleges to stabilize recruitment.

APAC Cell and Gene Therapy Contract Development and Manufacturing Organization Market

Asia Pacific is projected to deliver the fastest 16.12% CAGR through 2031, challenging historic dominance. China’s National Development and Reform Commission funded multiple industrial parks, with WuXi Biologics adding capacities in Singapore and the United States while simultaneously expanding its Wuxi campus. Japan’s Pharmaceuticals and Medical Devices Agency created a Fast Track similar to the US Breakthrough Therapy tag, cutting median review times by four months. South Korea’s Lotte Biologics has earmarked USD 3.3 billion for a 400,000 L plant in Incheon, signalling intent to anchor regional demand. Cost-competitive labour and modern infrastructure give the region pricing leverage that lures Western innovators into joint ventures.

Europe and Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization Market

Europe maintains a mature but slower-growth profile. EMA’s centralised authorisation system offers predictability, yet divergent national GMP inspections and higher energy costs temper agility. Lonza’s Visp campus and AGC Biologics’ Heidelberg facility continue to draw projects that value track record over price. Cross-border supply chains connect European batch release to Middle Eastern clinical sites, illustrating the region’s role as a regulatory fulcrum. Meanwhile, pockets of greenfield investment appear in Ireland and Portugal, driven by grants and skilled talent availability.

Regulatory Landscape

Cell and gene therapy CDMOs operate within biologics and ATMP frameworks that emphasize identity, purity, potency, and traceability across complex manufacturing chains. In the United States, the FDA created the Office of Therapeutic Products to streamline reviews. The agency has also continued to formalize a flexible approach to Chemistry, Manufacturing, and Controls for CGTs, including a May 2026 finalized guidance describing phase-appropriate GMP and risk-based comparability expectations while reaffirming underlying statutory requirements under the FDCA and PHSA.

In Europe, EMA remains central to ATMP oversight, and 2026 policy work under the EU Pharma Package has put governance changes and hospital exemption (HE) refinements in focus. This includes moves toward more centralized reporting and standardized quality and traceability expectations. For global sponsors and CDMOs, the shifts increase the premium on harmonized CMC dossiers (FDA-EMA-PMDA alignment), validated analytics, and auditable chain-of-identity and chain-of-custody systems during multi-region clinical supply and commercial inspections.

Value Chain Analysis

The CGT CDMO value chain starts with client discovery and IND-enabling work, including process development, analytical method development, and assay qualification. It then moves into manufacturing inputs and execution, where critical materials include plasmid DNA, viral vectors (notably AAV and lentivirus), single-use consumables, and qualified cell banks. For autologous programs, patient apheresis and collection feed into controlled inbound logistics, and sponsors and CDMOs increasingly use cryopreserved starting materials and standardized handling workflows to decouple collection sites from manufacturing slots and stabilize scheduling.

Core CDMO activities span upstream production, downstream purification, fill-finish, QC and lot release, and distribution under stringent cold-chain requirements, with COI and COC documentation tying together each handoff. Supporting layers, including digital quality and ERP and data systems (such as Veeva-aligned quality operations), and specialized logistics providers, are rising in importance as regulatory documentation expands and multi-site networks proliferate. Ongoing supply constraints around GMP-grade plasmid and viral raw materials, along with procurement exposure to imported bioprocess equipment and cold-chain components, keep sourcing strategy and supplier qualification as key value-chain differentiators for global CDMOs.

Market Opportunities and Future Outlook

A large installed pipeline (more than 2,000 clinical and pre-clinical projects) continues to drive demand for phase-appropriate CMC execution. FDA actions in 2026 that codify CMC flexibilities raise the value of CDMOs that can document risk-based comparability and control strategies across development stages. This is creating whitespace for providers that package process development, analytics, and regulatory-ready data into standardized platforms, particularly for viral-vector programs where long lot-release timelines and assay bottlenecks are common.

From an execution standpoint, opportunities cluster around (i) automation and closed-system manufacturing to reduce manual interventions that contribute to cost and batch-failure risk, and (ii) supply chain orchestration capabilities that strengthen COI/COC traceability across decentralized networks. Market activity in 2026 reflects these themes: Cellares secured a site in Leiden Bio Science Park for a European IDMO smart factory concept, while partnerships such as Andelyn Biosciences with ENCell show how sponsors and service providers are building regional manufacturing networks to simplify cross-border logistics and access capacity. Modular cleanroom expansions (for example, ISO 7 suite buildouts) also support faster reconfiguration across autologous, allogeneic, and viral-vector workflows, even as utilization remains uneven in some legacy facilities.